Down 13% from its year high at £116.50 now, AstraZeneca’s share price looks cheap to me anywhere under £219.81
AstraZeneca’s share price has dropped recently on concerns relating to its Chinese operation, but this may have left the ...
The AstraZeneca share price jumps 5% on today’s strong results – but is it too expensive?
Harvey Jones hails the brilliant long-term performance of the AstraZeneca share price, but wonders whether the FTSE 100's ...
BofA maintains Buy on AstraZeneca stock, GBP145.00 target
BofA Securities reiterated its Buy rating on AstraZeneca (NASDAQ:AZN:LN) (NASDAQ: AZN), with a steady price target of GBP145.00. The firm's positive stance is based on the pharmaceutical giant's ...
AstraZeneca initiated with an Overweight at Morgan Stanley
Morgan Stanley analyst Sarita Kapila initiated coverage of AstraZeneca (AZN) with an Overweight rating and 14,500 GBp price target The firm ...
Morgan Stanley sees huge upside at AstraZeneca
Morgan Stanley has initiated coverage of pharma giant AstraZeneca with an 'overweight' rating, recommending investors to ...
AstraZeneca Stock Rally Will be Tested by Answers on China Probe
A revival in AstraZeneca Plc shares faces a key test this week, with more likely to hinge on the drugmaker’s ability to ...
Sumitomo Mitsui Trust Group Inc. Has $5.58 Million Stock Position in AstraZeneca PLC (NASDAQ:AZN)
Sumitomo Mitsui Trust Group Inc. grew its stake in shares of AstraZeneca PLC (NASDAQ:AZN – Free Report) by 0.7% during the 4th quarter, according to its most recent 13F filing with the Securities & ...
Broker tips: AstraZeneca, Pan African Resources
UBS upgraded AstraZeneca from 'neutral' to 'buy' on Thursday, citing the pharmaceutical firm's "sector-leading" drug pipeline ...
AstraZeneca shares rise as China probe update reassures
AstraZeneca on Thursday said it could face a fine of up to $4.5 million in China over suspected unpaid import taxes, raising ...
Business Weekly8d
AstraZeneca leads FTSE charge with shares surge and higher dividend
Growing at a rate of knots from the Cambridge Biomedical Campus, AstraZeneca hoisted its market cap to £183.58 billion and ...
The Motley Fool UK8d
The AstraZeneca share price jumps 5% on today’s strong results – but is it too expensive?
Harvey Jones hails the brilliant long-term performance of the AstraZeneca share price, but wonders whether the FTSE 100’s biggest company is just too pricey. When investing, your capital is at risk.